Xeris Pharmaceuticals

About Xeris Pharmaceuticals

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company focused on developing and commercializing ready-to-use, liquid-stable injectables for various medical conditions. The company was founded in 2005 and is headquartered in Chicago, Illinois. Its foundation is built upon two proprietary formulation technology platforms, XeriSol and XeriJect, which aim to overcome the limitations of traditional aqueous-based formulations by allowing for smaller injection volumes and eliminating the need for refrigeration or reconstitution. The company's commercial portfolio includes several key products. Gvoke is a ready-to-use liquid glucagon for treating severe hypoglycemia in diabetic patients, available in both a pre-filled syringe and an auto-injector. This product provides a significant advancement over traditional glucagon emergency kits that require a multi-step mixing process. Keveyis is an FDA-approved therapy for primary periodic paralysis, a rare genetic disorder causing episodes of muscle weakness or paralysis. Another key product is Recorlev, designed for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome, a rare and serious endocrine disorder. Xeris generates revenue through the sale of these proprietary products. The business model targets both specialty and rare disease markets, addressing conditions with significant unmet medical needs. The company serves patients and healthcare providers through a commercial infrastructure that includes a U.S.-based field force. Xeris has achieved several milestones, including the initial public offering in 2018 and the strategic acquisition of Strongbridge Biopharma plc in 2021, which added Keveyis and Recorlev to its product lineup. The company continues to advance its pipeline, leveraging its formulation technologies to develop new therapies across endocrinology, neurology, and gastroenterology.